SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

Blood

Volumn 115, Issue 3, 2010, Pages 615-625

  Cristóbal, Ion ^a   Blanco, Francisco J ^b   Garcia Orti, Laura ^a   Marcotegui, Nerea ^a   Vicente, Carmen ^a   Rifon, José ^c   Novo, Francisco J ^a   Bandres, Eva ^a   Calasanz, María J ^a   Bernabeu, Carmelo ^b   Odero, María D ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYTARABINE; PROTEINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR EVI1; TRANSCRIPTION FACTOR PP2A; TRANSCRIPTION FACTOR SET; TRANSCRIPTION FACTOR SETBP1; UNCLASSIFIED DRUG; CARRIER PROTEIN; NUCLEAR PROTEIN; SETBP1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL GROWTH; COMPLEX FORMATION; CYTOGENETICS; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; GENE TRANSLOCATION; HEMATOPOIETIC STEM CELL; HUMAN; LABORATORY TEST; LEUKEMIA CELL; LEUKEMOGENESIS; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CLEAVAGE; RETROVIRUS; AMINO ACID SEQUENCE; CASE REPORT; CELL CULTURE; CELL STRAIN K 562; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; UPREGULATION;

AGED; AMINO ACID SEQUENCE; BASE SEQUENCE; CARRIER PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; MALE; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROGNOSIS; UP-REGULATION;

EID: 77449131060     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-227363     Document Type: Article

References (42)

1. Dohner H. Implication of the molecular characterization of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007:412-419.
2. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2): 115-136.
3. Loriaux MM, Levine RL, Tyner JW, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 2008; 111(9):4788-4796.
4. Tomasson MH, Xiang Z, Walgren R, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood. 2008;111(9):4797-4808.
5. Schoch C, Kohlmann A, Schnittger S, et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A. 2002;99(15):10008-10013.
6. Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004;350(16):1605-1616.
7. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16): 1617-1628.
8. Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res. 2005;65(2):375-378.
9. Paulsson K, Heidenblad M, Strombeck B, et al. High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia. 2006;20(5):840-846.
10. Rücker FG, Bullinger L, Schwaenen C, et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarraybased molecular characterization. J Clin Oncol. 2006;24(24):3887-3894.
11. Suela J, Alvarez S, Cifuentes F, et al. DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia. 2007;21(6):1224-1231.
12. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456(7218):66-72.
13. Cools J, Mentens N, Odero MD, et al. Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13). Blood. 2002;99(5):1776-1784.
14. Odero MD, Vizmanos JL, Roman JP, et al. A novel gene, MDS2, is fused to ETV6/TEL in a t(1; 12)(p36.1;p13) in a patient with myelodysplastic syndrome. Genes Chromosomes Cancer. 2002; 35(1):11-19.
15. Nucifora G, Laricchia-Robbio L, Senyuk V. EVI1 and hematopoietic disorders: history and perspectives. Gene. 2006;368:1-11.
16. Gallay N, Dos Santos C, Cuzin L, et al. The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia. 2009;23(6):1029-1038.
17. Coessens B, Thijs G, Aerts S, et al. INCLUSive: a web portal and service registry for microarray and regulatory sequence analysis. Nucleic Acids Res. 2003;31(13):3468-3470.
18. Bryne JC, Valen E, Tang MH, et al. JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update. Nucleic Acids Res. 2008;36(Database issue):D102-D106.
19. Matys V, Kel-Margoulis OV, Fricke E, et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 2006;34(Database issue):D108-D110.
20. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401-409.
21. Minakuchi M, Kakazu N, Gorrin-Rivas MJ, et al. Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET. Eur J Biochem. 2001;268(5):1340-1351.
22. Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science. 1992;257(5074): 1261-1264.
23. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8(5):355-368.
24. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. 1996; 271(19):11059-11062.
25. Cervoni N, Detich N, Seo SB, Chakravarti D, Szyf M. The oncoprotein Set/TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J Biol Chem. 2002; 277(28):25026-25031.
26. Beresford PJ, Zhang D, Oh DY, et al. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J Biol Chem. 2001;276(46): 43285-43293.
27. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 2003;112(5):659-672.
28. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 2001;353(3):417-439.
29. Wang GL, Iakova P, Wilde M, Awad S, Timchenko NA. Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity. Genes Dev. 2004; 18(8):912-925.
30. Kawabe T, Muslin AJ, Korsmeyer SJ. HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint. Nature. 1997;385(6615):454-458.
31. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell. 2007;130(1):21-24.
32. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 2008;14(4):152-160.
33. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev. 2005;15(1):34-41.
34. Schönthal AH. Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett. 2001; 170(1):1-13.
35. Beresford PJ, Xia Z, Greenberg AH, Lieberman J. Granzyme A loading induces rapid cytolysis and a novel form of DNA damage independently of caspase activation. Immunity. 1999;10(5):585-594.
36. Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell. 2001;104(1):119-130.
37. Kutney SN, Hong R, Macfarlan T, Chakravarti D. A signaling role of histone-binding proteins and INHAT subunits pp32 and Set/TAF-Ibeta in integrating chromatin hypoacetylation and transcriptional repression. J Biol Chem. 2004;279(29): 30850-30855.
38. Kandilci A, Mientjes E, Grosveld G. Effects of SET and SET-CAN on the differentiation of the human promonocytic cell line U937. Leukemia. 2004;18(2):337-340.
39. 2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. J Biol Chem. 2003;278(2):1158-1164.
40. Brennan CM, Gallouzi IE, Steitz JA. Protein ligands to HuR modulate its interaction with target mRNAs in vivo. J Cell Biol. 2000;151(1):1-14.
41. Büchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol. 2009;27(1):61-69.
42. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007;117(9):2408-2421.